Top Healthcare Technology Stocks To Buy Right Now

Skyworks Solutions (Nasdaq: SWKS  ) reported earnings on July 18. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 28 (Q3), Skyworks Solutions met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins grew across the board.

Revenue details
Skyworks Solutions notched revenue of $436.1 million. The 18 analysts polled by S&P Capital IQ expected to see sales of $436.0 million on the same basis. GAAP reported sales were 12% higher than the prior-year quarter's $389.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.54. The 18 earnings estimates compiled by S&P Capital IQ predicted $0.53 per share. Non-GAAP EPS of $0.54 for Q3 were 20% higher than the prior-year quarter's $0.45 per share. GAAP EPS of $0.34 for Q3 were 31% higher than the prior-year quarter's $0.26 per share.

10 Best China Stocks To Own Right Now: Five Prime Therapeutics Inc (FPRX)

Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

FP-1039

FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.

FPA008

FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.

FPA144

FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.

Advisors' Opinion:

• [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]

  Among the companies with shares expected to actively trade in Monday’s session are Keurig Green Mountain Inc.(GMCR), JA Solar Holdings Co.(JASO) and Five Prime Therapeutics Inc.(FPRX)

• [By Monica Gerson]

  Breaking news

  Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.

  Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top Healthcare Technology Stocks To Buy Right Now: Chesapeake Lodging Trust (CHSP)

Chesapeake Lodging Trust (the Trust) is a self-advised real estate investment trust (REIT). The Trust is focused on investments primarily in upper-upscale hotels in business and convention markets and, on a selective basis, select-service and extended-stay hotels in urban settings or locations in the United States of America. All of the Trust�� assets are held by, and all of its operations are conducted through, Chesapeake Lodging, L.P., its operating partnership (the Operating Partnership). The Operating Partnership leases its hotels to CHSP TRS LLC (CHSP TRS), which is a wholly owned subsidiary of the Operating Partnership. CHSP TRS engages hotel management companies to operate the hotels pursuant to management agreements. CHSP TRS is a taxable REIT subsidiary (TRS). As of December 31, 2011, the Trust owned 12 hotels with an aggregate of 3,516 rooms in six states and the District of Columbia. In August 2012, the Company acquired the 520-room W Chicago-Lakeshore located in Chicago, Illinois from Starwood Hotels & Resorts Worldwide Inc. (Starwood). The Trust entered into a long-term management agreement with Starwood to continue operating the hotel under the W flag. In September 2012, it acquired the 429-room Hyatt Regency Mission Bay Spa and Marina, located in San Diego, California. In October 2012, the Company acquired 222-room The Hotel Minneapolis, a Marriott Autograph Collection hotel, located in Minneapolis. In March 2013, the Company acquired 185-room Hyatt Place New York Midtown South, located in New York. In April 2013, Starwood Hotels & Resorts Worldwide Inc completed the sale of W New Orleans - French Quarter to Chesapeake Lodging Trust. In April 2013, Chesapeake Lodging Trust acquires W New Orleans From Starwood Hotels & Resorts Worldwide Inc. In June 2013, Chesapeake Lodging Trust purchased the Hyatt Fisherman's Wharf from Hyatt Hotels Corp. Effective June 27, 2013, Chesapeake Lodging Trust acquired Hyatt Santa Barbara.

On December 22, 2011, the Trust acquired Holiday Inn ! New York City Midtown, which had 122 rooms. On October 3, 2011, the Trust acquired Denver Marriott City Center hotel, which had 613 rooms. On July 8, 2011, it acquired Hotel Adagio, which consisted of 171 rooms. On June 30, 2011, the Trust acquired Courtyard Washington Capitol Hill/Navy Yard hotel, which had 204 rooms. On June 17, 2011, it acquired Hotel Indigo San Diego Gaslamp Quarter, which consisted of 210 rooms. On May 10, 2011, the Trust acquired W Chicago - City Center hotel, which had 368 rooms. On May 2, 2011, it acquired Homewood Suites Seattle Convention Center hotel, which had 195 rooms.

The Company has management agreements with third parties to manage its hotels. The Trust's hotel managers provide managerial and other hotel employees, oversee operations and maintenance, prepare reports, budgets and projections and provide other administrative and accounting support services. Its management agreements provide for base management fees ranging from 1% to 4% of gross hotel revenues and incentive compensation if hotel operating income. Of its 12 hotels, seven operates pursuant to franchise agreements from international hotel companies. The Trust�� lease agreements are inter-company agreements between its property-owning subsidiaries and its TRS lessees.

Advisors' Opinion:

• [By Rich Duprey]

  Real estate investment trust�Chesapeake Lodging Trust� (NYSE: CHSP  ) �announced yesterday its second-quarter dividend of $0.24 per share, the same rate it paid last quarter after raising the payout 9% from $0.22 per share.

Top Healthcare Technology Stocks To Buy Right Now: Rosetta Resources Inc.(ROSE)

Rosetta Resources Inc., an independent exploration and production company, engages in the acquisition, exploration, development, and production of onshore oil and gas resources in the United States. It owns producing and non-producing oil and gas properties located primarily in South Texas, including the Eagle Ford, and in the Southern Alberta Basin in Northwest Montana. As of December 31, 2011, the company had an estimated 965 billion cubic feet equivalent of proved reserves, including 36,370 million barrels of oil, 50,219 million barrels of natural gas liquids, and 446 billion cubic feet of natural gas, as well as drilled 53 net wells. Rosetta Resources Inc. was incorporated in 2005 and is headquartered in Houston, Texas.

Advisors' Opinion:

• [By Value Digger]

  It is clear that these key metrics match the metrics of a heavily natural gas weighted company that also carries significant debt. To prove this, let's check out Comstock Resources (CRK). Comstock sold some assets recently to Rosetta Resources (ROSE) to reduce its long term debt which still remains high though.

• [By Vera Yuan]

  ��il and gas exploration and production company Rosetta Resources, Inc. (ROSE) rose in anticipation of an ease in regulations on the exportation of condensate, an ultra-light oil that undergoes minimal processing. This could allow the condensate to be exported at higher prices, alleviating a potential condensate glut in the U.S. and benefitting Rosetta.

Top Healthcare Technology Stocks To Buy Right Now: Guggenheim Multi-Asset Income ETF (CVY)

The Guggenheim Multi-Asset Income ETF (the Fund), formerly Claymore/Zacks Multi-Asset Income Index ETF, seeks investment results that correspond generally to the performance of an equity index called the Zacks Multi-Asset Income Index (the Index). The Index consists of approximately 125 to 150 securities selected, based on investment and other criteria, from a universe of domestic and international companies. The universe of securities within the Index includes United States-listed common stocks, American depositary receipts (ADRs) paying dividends, real estate investment trusts, master limited partnerships, closed-end funds and traditional preferred stocks. The companies in the universe are selected using a methodology developed by the index provider, Zacks Investment Research, Inc. The Fund, using a passive or indexing investment approach, seeks to replicate the performance of the Index. The Fund�� investment advisor is Claymore Advisors, LLC. Advisors' Opinion:

• [By Genia Turanova]

  Moreover, investors can do one-stop shopping for most income classes through a single ETF as well. One interesting choice here is Guggenheim Multi-Asset Income (CVY).